Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties

著者: Christian P. Larsen, Thomas C. Pearson, Andrew Adams, Paul L. Tso, Nozomu Shirasugi, Elizabeth Strobertb, Dan Anderson, Shannon Cowan, Karen Price, Joseph Naemura, John Emswiler, JoAnne L. Greene, Lori A. Turk, Jürgen Bajorath, Robert Townsend, David Hagerty, Peter S. Linsley, Robert Peach - American Journal of Transplantation 2005 被引用: 710

Current success in organ transplantation is dependent upon the use of calcineurin-inhibitor-based im-munosuppressive regimens. Unfortunately, current immunotherapy targets molecules with ubiquitous ex-pression resulting in devastating non-immune side effects. T-cell costimulation has been identified as a new potential immunosuppressive target. The best characterized pathway includes CD28, its homologue CTLA4 and their ligands CD80 and CD86. While an im-munoglobulin fusion protein construct of CTLA4 sup-pressed rejection in rodents, it lacked efficacy in primate transplant models. In an attempt to increase the biologic potency of the parent molecule a novel, modified version of CTLA4-Ig, LEA29Y (belatacept), was constructed. Two amino acid substitutions (L104E and A29Y) gave rise to slower dissociation rates for both CD86 and CD80. The increased avidity resulted in a 10fold increase in potency in vitro and significant prolongation of renal allograft survival in a pre-clinical primate model. The use of immunoselective biologics may provide effective maintenance immunosuppression while avoiding the collateral toxicities associated with conventional immunsuppressants. Current success in organ transplantation is dependent upon the use of calcineurin-inhibitor-based im-munosuppressive regimens. Unfortunately, current immunotherapy targets molecules with ubiquitous ex-pression resulting in devastating non-immune side effects. T-cell costimulation has been identified as a new potential immunosuppressive target. The best characterized pathway includes CD28, its homologue CTLA4 and their ligands CD80 and CD86. While an im-munoglobulin fusion protein construct of CTLA4 sup-pressed rejection in rodents, it lacked efficacy in primate transplant models. In an attempt to increase the biologic potency of the parent molecule a novel, modified version of CTLA4-Ig, LEA29Y (belatacept), was constructed. Two amino acid substitutions (L104E and A29Y) gave rise to slower dissociation rates for both CD86 and CD80. The increased avidity resulted in a 10fold increase in potency in vitro and significant prolongation of renal allograft survival in a pre-clinical primate model. The use of immunoselective biologics may provide effective maintenance immunosuppression while avoiding the collateral toxicities associated with conventional immunsuppressants.